LEADER 03393nam 22006494a 450 001 9910830531903321 005 20230617005800.0 010 $a1-280-27251-1 010 $a9786610272518 010 $a0-470-66753-2 010 $a0-470-86997-6 010 $a0-470-86999-2 035 $a(CKB)1000000000356010 035 $a(EBL)232716 035 $a(SSID)ssj0000112065 035 $a(PQKBManifestationID)11137879 035 $a(PQKBTitleCode)TC0000112065 035 $a(PQKBWorkID)10081583 035 $a(PQKB)10213077 035 $a(MiAaPQ)EBC232716 035 $a(OCoLC)85820915 035 $a(EXLCZ)991000000000356010 100 $a20040701d2004 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBiology of IGF-1$b[electronic resource] $eits interaction with insulin in health and malignant states /$f[edited by Gregory Bock, Jamie Goode] 210 $aThe Atrium, Southern Gate, Chichester, UK ;$aHoboken, NJ $cJohn Wiley & Sons$dc2004 215 $a1 online resource (294 p.) 225 1 $aNovartis Foundation symposium ;$v262 300 $aDescription based upon print version of record. 311 $a0-470-86998-4 320 $aIncludes bibliographical references and indexes. 327 $aCirculating IGF-I and its role in cancer: lessons from the IGF-1 gene-deletion (LID) mouse -- Physiology of the IGF system -- Molecular basis of insulin action -- IGF-1 and insulin as growth hormones -- Insulin-like growth factors and neoplasia -- Loss of IGF2 imprinting: mechanisms and consequences -- Insulin and IGF-1 receptor trafficking and signalling -- The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb -- Structural biology of insulin and IGF-1 receptors -- Genetic blockade of the insulin-like growth factor-I receptor for human malignancy -- IGF-1 and prostate cancer -- IGF-1 and breast cancer -- IGFBPs and cancer -- The IGF receptor as anticancer treatment target -- Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. 330 $aAn invaluable book containing a series of interdisciplinary discussions between clinical and basic scientists. Biology of IGF-1: Its interaction with insulin and health and malignant states focuses on key issues such as:the definition of danger zonesthe development of methods for early recognition of malignant states linked to IGF-1 and/or insulinpossible approaches to preventative interventionthe relevance in this field of research to the development of novel therapeutic approaches to treating certain cancers. 410 0$aNovartis Foundation symposium ;$v262. 606 $aSomatomedin$xPhysiological effect$vCongresses 606 $aSomatomedin$xPathophysiology$vCongresses 606 $aCarcinogenesis$vCongresses 615 0$aSomatomedin$xPhysiological effect 615 0$aSomatomedin$xPathophysiology 615 0$aCarcinogenesis 676 $a612.01575 676 $a612/.015756 686 $a44.78$2bcl 701 $aBock$b Gregory$0322650 701 $aGoode$b Jamie$0283336 712 12$aSymposium on Biology of IGF-1 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830531903321 996 $aBiology of IGF-1$94025856 997 $aUNINA